DelveInsight's "Wet Age-Related Macular Degeneration (Wet AMD) Market" report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the Wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the Wet Age-Related Macular Degeneration Market Research Report
- The introduction of Anti-vascular endothelial growth factor (VEGF) as a standard Wet AMD treatment has led to a significant improvement in patients' prognosis, allowing recovery and maintenance of visual function in the vast majority of cases.
- Anti-VEGF medications have been revolutionary for treating neovascular, or exudative, age-related macular degeneration, but unmet needs continue. Firstly, intravitreal injections require frequent and indefinite evaluations, with an exceptionally high burden during the first two treatment years. Secondly, current treatments have a short duration of effect. Lastly, despite robust response and visual gains in many patients, up to 30% may continue to lose vision from baseline due to inadequate choroidal neovascularization response, the progression of atrophy or subretinal fibrosis, and scar formation.
- Some of the dominant players such as Roche, Kodiak Sciences, REGENXBIO, Chengdu Kanghong Biotech, Opthea Limited, Alkahest, Graybug Vision, PanOptica, Clearside Biomedical, Hemera Biosciences, Ribomic USA Inc., and others are set to influence the global Wet AMD market.
- Wet Age-Related Macular Degeneration Market is positively impacted by an increased prevalence and the expected launch of novel therapies, such as RGX-314, Conbercept, Faricimab, Beovu, Axitinib, HMR59, RBM-007, KSI-301, OPT-302, AKST4290, Sunitinib Malate, RGX-314, PAN-90806, and others during the forecast period (2017–2030).
For further information on Market Impact by Therapies, visit: Wet AMD Treatment Market Trends
Age-related Macular Degeneration (AMD) is a leading cause of severe, irreversible blindness worldwide, profoundly affecting individuals' quality of life. Wet AMD is a type of AMD characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid that may swell and damage the macula. Wet AMD is also referred to as neovascular AMD, accounts for roughly 10% of AMD cases, but almost 90% of AMD-related central vision loss.
According to DelveInsight's analysts, the total diagnosed Wet AMD prevalent population was estimated to be 4,426,968 cases in the 7MM in 2020. Also, it has been observed that Wet Age-Related Macular Degeneration is more prominent in females as compared to males.
The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into:
- Total prevalent cases
- Gender-specific cases
- Age-specific cases
Get a sample copy of this report: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Wet Age-Related Macular Degeneration Treatment Market
Wet AMD has no cure even though an appropriate treatment could delay disease progression, avoiding the negative impact of vision loss on these patients' quality of life. According to the most recent AMD guidelines, the intravitreal administration of antivascular endothelial growth factor agents (anti-VEGF) constitutes the standard of care for Wet AMD patients due to the promising results provided by these therapies during clinical development.
Angiogenesis inhibitors, the protein that promotes blood vessel growth, work by blocking VEGF activity. The most common and effective clinical treatment for Wet AMD is anti-VEGF therapy, a periodic intravitreal injection of a chemical called an anti-VEGF. Several VEGF therapies have been approved in the market for 7MM. These include Lucentis, Eylea, Macugen, and Boevu. Avastin is also used as an "off-label" drug.
However, the success of anti-VEGF therapy is closely linked to strict intravitreal treatment patterns that seem not to be appropriately addressed in routine clinical practice, conducting more preliminary outcome results for Wet AMD patients than expected according to clinical trials.
Photodynamic therapy (PDT) is most effective in a subtype of Wet AMD known as predominantly classic subfoveal AMD, in which blood vessel growth and leakage in the fovea are well defined. PDT is rarely utilized now since there are drugs (EYLEA, Lucentis, Macugen, and Avastin), which prohibit the vessel-promoting VEGF protein. During the PDT procedure, a drug known as Visudyne is injected into the arm. The drug courses through the body and is absorbed by the fragile, draining blood vessels in the eye.
Laser photocoagulation surgery was the first treatment used for Wet AMD. However, it is only an option for a few patients. During the outpatient procedure, the eye is numbed, and a high-energy laser heats, seals, and damages abnormal leaky blood vessels. This can potentially stop further vision loss; however, it leads to a permanent blind spot because of scarring. Some patients experience mild pain during and/or shortly after the procedure.
Researchers have been suggesting antioxidant vitamins, and other nutrients may reduce AMD progression among people with a high risk of vision loss from macular degeneration. Two large clinical trials sponsored by the National Eye Institute (NEI) called the Age-Related Eye Disease Studies (AREDS and AREDS2) evaluated the effect of nutritional supplements on macular progression degeneration among people with various stages of AMD.
Wet AMD Emerging Therapies Along with Key Players
- Faricimab: Roche
- Conbercept: Chengdu Kanghong Biotech
- KSI-301: Kodiak Sciences Inc.
- OPT-302: Opthea Limited
- AKST4290: Alkahest Inc.
- Sunitinib Malate: Graybug Vision
- RGX-314: REGENXBIO
- PAN-90806: PanOptica, Inc.
- Axitinib: Clearside Biomedical
- HMR59: Hemera Biosciences
- RBM-007: Ribomic USA Inc.
And several others.
Get a sample copy of this report: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Wet Age-Related Macular Degeneration Market Drivers
- Drugs in Pipeline - Many products are in the pipeline like Faricimab, KSI-301, OPT-302, which will help expand the market.
- Diagnosis- Several diagnostic tests have been developed, including fluorescein angiography, indocyanine green angiography, and optical coherence tomography, to help in timely diagnosis.
- Increased Prevalence - A huge patient pool allows any entrant access to a big market to realize substantial gains.
- Genetic Therapy - Several genetic therapies are being developed, which can yield substantial gains for new entrants.
- Extensive R&D and Personalized treatment
Wet Age-Related Macular Degeneration Market Barriers
- Cost of Therapy - The high cost of therapy with gene therapy presents a considerable hurdle to access treatment.
- Launch of Biosimilars - There is a lack of biomarkers to predict disease incidence, identify at-risk individuals, elucidate causative pathophysiological etiologies, guide screening, monitoring, and treatment parameters to predict disease outcomes.
- Future competition among similar drugs - Anti VEGF drugs will compete with each other, which could prove to be a barrier for new entrants.
- Unmet needs associated with VEGF treatment - There are several unmet needs related to VEGF treatment, including loss of vision in almost 30% of patients getting treatment, and intravitreal injections require frequent and indefinite evaluations.
Scope of the Wet Age-Related Macular Degeneration Market Insight Report
- Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
- Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
- Wet Age-Related Macular Degeneration Markets Segmentation: By Geographies and By Wet Age-Related Macular Degeneration Therapies (Historical and Forecasted, Current and Upcoming)
- Dominant Market Companies investigating its candidates for Wet Age-Related Macular Degeneration: Roche, Kodiak Sciences, REGENXBIO, Chengdu Kanghong Biotech, Opthea Limited, Alkahest, Graybug Vision, PanOptica, Clearside Biomedical, Hemera Biosciences, Ribomic USA Inc, and several others.
- Analysis: Comparative and conjoint analysis of emerging therapies.
- Case Studies
- KOL's Views
- Analyst's View
Request for a Webex demo of the report or Get a sample copy of this report: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Table of Contents
| 1 | Key Insights on Wet Age-Related Macular Degeneration (Wet AMD) |
| 2 | Executive Summary of Wet AMD |
| 3 | Organizations |
| 4 | Wet Age-Related Macular Degeneration Market Overview at a Glance |
| 5 | Disease Overview: Wet Age-Related Macular Degeneration |
| 6 | Wet AMD Epidemiology and Patient Population |
| 7 | The United States |
| 8 | EU5 Countries Wet AMD Epidemiology |
| 8.1. | Germany |
| 8.2. | France |
| 8.3. | Italy |
| 8.4. | Spain |
| 8.5. | The United Kingdom |
| 9 | Japan Wet AMD Epidemiology |
| 10 | Wet Form Age-Related Macular Degeneration Treatment |
| 11 | Wet Age-Related Macular Degeneration Unmet Needs |
| 12 | Wet Age-Related Macular Degeneration Marketed Drugs |
| 12.1 | Eylea: Regeneron Pharmaceuticals |
| 12.2 | Beovu: Novartis |
| 12.3 | Lucentis: Novartis |
| 12.4 | Macugen: Pfizer |
| 13 | Wet Age-Related Macular Degeneration Emerging Therapies |
| 13.1 | Key cross competition |
| 13.2 | Faricimab: Roche |
| 13.3 | Conbercept: Chengdu Kanghong Biotech |
| 13.4 | KSI-301: Kodiak Sciences Inc. |
| 13.5 | OPT-302: Opthea Limited |
| 13.6 | AKST4290: Alkahest Inc. |
| 13.7 | Sunitinib Malate: Graybug Vision |
| 13.8 | RGX-314: REGENXBIO |
| 13.9 | PAN-90806: PanOptica, Inc. |
| 13.10 | Axitinib: Clearside Biomedical |
| 13.11 | HMR59: Hemera Biosciences |
| 13.12 | RBM-007: Ribomic USA Inc. |
| 14 | 7MM Wet Age-Related Macular Degeneration Market Analysis |
| 14.1 | Wet AMD Market Outlook by Country |
| 15 | The United States Wet Age-Related Macular Degeneration Market Outlook |
| 16 | EU-5 Wet Age-Related Macular Degeneration Market Outlook |
| 16.1 | Germany Market Size |
| 16.2 | France Market Size |
| 16.3 | Italy Market Size |
| 16.4 | Spain Market Size |
| 16.5 | The United Kingdom Market Size |
| 17 | Japan Wet Age-Related Macular Degeneration Market Outlook |
| 18 | Wet Age-Related Macular Degeneration Market Drivers |
| 19 | Wet Age-Related Macular Degeneration Market Barriers |
| 20 | Wet Age-Related Macular Degeneration SWOT Analysis |
| 21 | Wet Age-Related Macular Degeneration Market Access |
| 22 | Case Studies |
| 23 | KOL Views |
| 24 | Bibliography |
| 25 | Appendix |
| 26 | DelveInsight Capabilities |
| 27 | Disclaimer |
| 28 | About DelveInsight |
Media Contact
Company Name: DelveInsight
Contact Person: Ankit Nigam
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
